Celcuity Inc (CELC) - News Archive

Advancements in Targeted Oncology: An Overview of Celcuity s Latest Findings and Future Directions Breast cancer remains one of the most prevalent and challenging malignancies to treat, requiring continuous efforts in r...

Pioneering Progress in Breast Cancer Treatment: Gedatolisib Shows Potential as a Game Changer: Recent findings from Celcuity Inc. regarding the efficacy of gedatolisib in treating hormone receptor positive (HR+), human...

In a significant development for cancer treatment, Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focusing on the development of targeted therapies for oncology, announced its plan to initiate a Ne...

Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy for HR+, HER2- Advanced Breast Cancer: Insights from a Phase 1b Study The exploration of novel therapeutic combinations for hormone receptor-p...

Celcuity Inc., a clinical-stage biotechnology company focused on targeted therapies for oncology, recently revealed the pricing of their underwritten common stock offering. The offering includes 3,871,000 shares of comm...

Celcuity Inc., a pioneering clinical-stage biotechnology company specializing in the development of targeted therapies for oncology, has made a significant announcement that holds immense promise for patients with HR+/H...

Celcuity Inc., a clinical-stage biotechnology company, has initiated a Phase 1b/2 clinical trial (CELC-G-201) to evaluate the effectiveness of gedatolisib in combination with Nubeqa for the treatment of metastatic castr...